TECHNOLOGY FOCUS - INORGANIC CHEMISTRY - Preferred Components: The metal in the chelate is from the periodic table groups V (iron, cobalt, nickel, ruthenium, rhodium, palladium, osmium, iridium and platinum), IVB (lead, tin and germanium), IIIA (scandium, yttrium, lanthanides and actinides), (IIIB) (boron, aluminum, gallium, indium and thallium), IA (lithium, sodium, potassium, rubidium, cesium and francium) or IIA (beryllium, magnesium, calcium, strontium, barium and radium). The metal is: gadolinium, iron, manganese (Mn+2) and (Mn+3) or chromium (Cr+3); and lead, plutonium, iron, calcium, mercury, gold or other heavy metals and their ions.Preferred Components: The dendritic polymer is polyamidoamine or poly(propyleneimine) dendrimers. The dendritic polymer has as its surface groups hydroxyl and sulfhydryl groups. The dendritic polymer is a generation (G), EDTA core and tris-OH surface polyamidoamine dendrimer.    TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Components: The chelating agent or ligand is: linear organic acids, macrocyclics, macrocyclic derivatives, kryptates, phosphines, thioalkyl ethers, carboxylates, thioureas, phosphonic acids, methylenephosphonic acids, sulfonic acids or macrocyclic polypeptides; and diethylenetriaminepentaacetic acid, nitrilotriacetic acid, EDTA, hydroxyethylethylenediaminetriacetic acid, trans-1,2-diaminocyclohexanetetraacetic acid, 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid, 1,4,7,10-tetraazacyclododecanetetraacetic acid , 2-(p-isothiocyanatobenzyl)-6-methyl-diethylenetriaminepentaacetic acid, hydroxypyridinone or tris-(2-dimethylaminoethy) amine (TREN)-1-methyl-3,2-hydroxypyridinone (preferably gadolinium diethylenetriaminepentaacetic acid).    TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Components: (I) Is associated with dendritic polymer surface target directors, proteins, DNA, RNA (including single strands) or any other moieties that assist in diagnosis, therapy or delivery of (I). ACTIVITY - Antidote. No biological data is given.    MECHANISM OF ACTION - Chelation therapy.    ADMINISTRATION - Administration of (I) is via injection, oral, or intravenous. (I) Is in the form of a tablet, ampoule, powder or liquid (all claimed). No dosage details given.    EXAMPLE - A methanol solution (2 g) of dendritic polymer (polyamidoamine, ethylenediaminetetraacetic acid core and generation 4) was dried under vacuum to give dry dendrimer (226 mg). Water (6.5 ml) was added to dissolve the dendrimer. Then chelate (1100 mg) was added to the solution. The mixture was stirred for 48 hours. A solution of 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (1.5 g) was added to the reaction mixture. The reaction was stirred for 24 hour. Dialysis of the solution against water was done using 1000 cutt-off cellulose membrane for 4.5 hours. The solvent was removed by rotary evaporation. The residue was put on high vacuum to give encapsulated chelate dendritic polymer (1.276 g).